

CHINA MEDICINE CORP
Form 8-K
December 29, 2010

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 29, 2010

CHINA MEDICINE CORPORATION
(Exact name of registrant as specified in Charter)

Nevada
(State of Incorporation)

000-51379
(Commission File
Number)

51-0539830
(IRS Employer
Identification No.)

2/F, Guangri Tower
No. 9 Siyouan Road 1st Street
Yuexiu District
Guangzhou, China 510600
(Address of registrant's principal executive office)

(8620) 8739-1718 and (8620) 8737-8212
(Registrant's telephone number, including area code)

Check the appropriate box below in the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

On December 29, 2010, China Medicine Corporation (the "Company") issued a press release announcing that the Company's Board of Directors (the "Board") has authorized a second stock repurchase plan (the "Repurchase Plan"). Under the Repurchase Plan, the Board approved the repurchase of up to an additional \$2,000,000 worth of shares of the Company's common stock in the open market or in privately negotiated transactions from time to time, in compliance with Rule 10b-5, Rule 10b5-1 and Rule 10b-18 of the Securities and Exchange Commission. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item Financial Statements and Exhibits
9.01

(d) Exhibits.

The following is filed as an exhibit to this report:

Exhibit No.	Description
99.1	Press Release of China Medicine Corporation, December 29, 2010.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHINA MEDICINE
CORPORATION

By: /s/ Senshan Yang
Name: Senshan Yang
Title: Chief Executive Officer

Date: December 29, 2010
